However, the response rate of HCC patients to these EGFR tyrosine kinase inhibitors (TKIs) is low, and combination of sorafenib with EGFR TKIs did not provide additional benefit to HCC patients [37, 38]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.